Geron is a clinical-stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Imetelstat is designed to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.
|HQ||Menlo Park, US||Map|
Net income (FY, 2018)
EBIT (FY, 2018)
Market capitalization (11-Oct-2019)
Closing stock price (11-Oct-2019)
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2014||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018|
General and administrative expense
Operating expense total
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2014||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018|
When was Geron founded?
Geron was founded in 1990.
Who are Geron key executives?
Geron's key executives are John A. Scarlett, Olivia K. Bloom and Melissa A. Kelly Behrs.
How many employees does Geron have?
Geron has 17 employees.
Who are Geron competitors?
Competitors of Geron include Aptevo Therapeutics, Aeglea Biotherapeutics and Cleveland BioLabs.
Where is Geron headquarters?
Geron headquarters is located at 149 Commonwealth Dr, Menlo Park.
Where are Geron offices?
Geron has offices in Menlo Park and Canton.
How many offices does Geron have?
Geron has 2 offices.
Receive alerts for 300+ data fields across thousands of companies